{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:15:31Z","timestamp":1793949331510,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00059-023-05189-z","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T09:02:26Z","timestamp":1686214946000},"page":"266-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pulmonary hypertension associated with left heart disease","Pulmonale Hypertonie in Verbindung mit Linksherzerkrankungen"],"prefix":"10.1007","volume":"48","author":[{"given":"Max","family":"Wissm\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Dohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurin","family":"Ochs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Tichelb\u00e4cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"5189_CR1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert\u00a0M, Kovacs\u00a0G, Hoeper\u00a0MM et\u00a0al (2022) 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart\u00a0J 43:3618\u20133731","journal-title":"Eur Heart J"},{"key":"5189_CR2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","volume":"37","author":"S Rosenkranz","year":"2016","unstructured":"Rosenkranz\u00a0S, Gibbs\u00a0JSR, Wachter\u00a0R et\u00a0al (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart\u00a0J 37:942\u2013954","journal-title":"Eur Heart J"},{"key":"5189_CR3","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jacc.2017.01.051","volume":"69","author":"M Guazzi","year":"2017","unstructured":"Guazzi\u00a0M, Naeije\u00a0R (2017) Pulmonary hypertension in heart failure: pathophysiology, pathobiology, and emerging clinical perspectives. J\u00a0Am Coll Cardiol 69:1718\u20131734","journal-title":"J Am Coll Cardiol"},{"key":"5189_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01897-2018","author":"J-L Vachi\u00e9ry","year":"2019","unstructured":"Vachi\u00e9ry\u00a0J\u2011L, Tedford\u00a0RJ, Rosenkranz\u00a0S et al (2019) Pulmonary hypertension due to left heart disease. Eur Respir\u00a0J. https:\/\/doi.org\/10.1183\/13993003.01897-2018","journal-title":"Eur Respir J"},{"key":"5189_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","volume":"40","author":"M Obokata","year":"2019","unstructured":"Obokata\u00a0M, Reddy\u00a0YNV, Melenovsky\u00a0V et\u00a0al (2019) Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart\u00a0J 40:689\u2013697","journal-title":"Eur Heart J"},{"key":"5189_CR6","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","volume":"35","author":"V Melenovsky","year":"2014","unstructured":"Melenovsky\u00a0V, Hwang\u00a0SJ, Lin\u00a0G et\u00a0al (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart\u00a0J 35:3452\u20133462","journal-title":"Eur Heart J"},{"key":"5189_CR7","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","volume":"43","author":"K Omote","year":"2022","unstructured":"Omote\u00a0K, Sorimachi\u00a0H, Obokata\u00a0M et\u00a0al (2022) Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. Eur Heart\u00a0J 43:3417\u20133431","journal-title":"Eur Heart J"},{"key":"5189_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00059-019-4823-6","volume":"44","author":"T Tichelb\u00e4cker","year":"2019","unstructured":"Tichelb\u00e4cker\u00a0T, Dumitrescu\u00a0D, Gerhardt\u00a0F et\u00a0al (2019) Pulmonary hypertension and valvular heart disease. Herz 44:491\u2013501","journal-title":"Herz"},{"key":"5189_CR9","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","volume":"133","author":"BA Maron","year":"2016","unstructured":"Maron\u00a0BA, Hess\u00a0E, Maddox\u00a0TM et\u00a0al (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a\u00a0large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation 133:1240\u20131248","journal-title":"Circulation"},{"key":"5189_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1164\/rccm.201706-1215OC","volume":"197","author":"P Douschan","year":"2018","unstructured":"Douschan\u00a0P, Kovacs\u00a0G, Avian\u00a0A et\u00a0al (2018) Mild elevation of pulmonary arterial pressure as a\u00a0predictor of mortality. Am J Respir Crit Care Med 197:509\u2013516","journal-title":"Am J Respir Crit Care Med"},{"key":"5189_CR11","doi-asserted-by":"publisher","first-page":"e009729","DOI":"10.1161\/JAHA.118.009729","volume":"7","author":"D Kolte","year":"2018","unstructured":"Kolte\u00a0D, Lakshmanan\u00a0S, Jankowich\u00a0MD et al (2018) Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J\u00a0Am Heart Assoc 7:e9729","journal-title":"J Am Heart Assoc"},{"key":"5189_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","volume":"8","author":"BA Maron","year":"2020","unstructured":"Maron\u00a0BA, Brittain\u00a0EL, Hess\u00a0E et\u00a0al (2020) Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a\u00a0retrospective cohort study. Lancet Respir Med 8:873\u2013884","journal-title":"Lancet Respir Med"},{"key":"5189_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","volume":"3","author":"RR Vanderpool","year":"2018","unstructured":"Vanderpool\u00a0RR, Saul\u00a0M, Nouraie\u00a0M et\u00a0al (2018) Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 3:298\u2013306","journal-title":"JAMA Cardiol"},{"key":"5189_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ejhf.860","volume":"20","author":"M Palazzini","year":"2018","unstructured":"Palazzini\u00a0M, Dardi\u00a0F, Manes\u00a0A et\u00a0al (2018) Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC\/ERS guidelines and insights for future changes. Eur J Heart Fail 20:248\u2013255","journal-title":"Eur J Heart Fail"},{"key":"5189_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.116.022362","volume":"141","author":"S Rosenkranz","year":"2020","unstructured":"Rosenkranz\u00a0S, Howard\u00a0LS, Gomberg-Maitland\u00a0M, Hoeper\u00a0MM (2020) Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 141:678\u2013693","journal-title":"Circulation"},{"key":"5189_CR16","doi-asserted-by":"publisher","first-page":"e009047","DOI":"10.1161\/CIRCIMAGING.119.009047","volume":"12","author":"K Tello","year":"2019","unstructured":"Tello\u00a0K, Wan\u00a0J, Dalmer\u00a0A et al (2019) Validation of the tricuspid annular plane systolic excursion\/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Circ Cardiovasc Imaging 12:e9047","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"5189_CR17","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.healun.2022.09.005","volume":"41","author":"C Fauvel","year":"2022","unstructured":"Fauvel\u00a0C, Raitiere\u00a0O, Boucly\u00a0A et\u00a0al (2022) Interest of TAPSE\/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. J\u00a0Heart Lung Transplant 41:1761\u20131772","journal-title":"J Heart Lung Transplant"},{"key":"5189_CR18","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jcmg.2016.12.024","volume":"10","author":"M Guazzi","year":"2017","unstructured":"Guazzi\u00a0M, Dixon\u00a0D, Labate\u00a0V et\u00a0al (2017) RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imaging 10:1211\u20131221","journal-title":"JACC Cardiovasc. Imaging"},{"key":"5189_CR19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamacardio.2019.3345","volume":"4","author":"JH Huston","year":"2019","unstructured":"Huston\u00a0JH, Maron\u00a0BA, French\u00a0J et\u00a0al (2019) Association of mild echocardiographic pulmonary hypertension with mortality and right ventricular function. JAMA Cardiol 4:1112\u20131121","journal-title":"JAMA Cardiol"},{"key":"5189_CR20","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 42:3599\u20133726","journal-title":"Eur Heart J"},{"key":"5189_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian\u00a0A, Beyersdorf\u00a0F, Praz\u00a0F et\u00a0al (2022) 2021 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart\u00a0J 43:561\u2013632","journal-title":"Eur Heart J"},{"key":"5189_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/heartjnl-2011-300705","volume":"98","author":"O Gaemperli","year":"2012","unstructured":"Gaemperli\u00a0O, Moccetti\u00a0M, Surder\u00a0D et al (2012) Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 98:126\u2013132","journal-title":"Heart"},{"key":"5189_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ejhf.864","volume":"20","author":"E Tigges","year":"2018","unstructured":"Tigges\u00a0E, Blankenberg\u00a0S, von Bardeleben\u00a0RS et\u00a0al (2018) Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 20:585\u2013594","journal-title":"Eur J Heart Fail"},{"key":"5189_CR24","doi-asserted-by":"publisher","first-page":"e002358","DOI":"10.1161\/CIRCINTERVENTIONS.114.002358","volume":"8","author":"CJ O\u2019Sullivan","year":"2015","unstructured":"O\u2019Sullivan\u00a0CJ, Wenaweser\u00a0P, Ceylan\u00a0O et\u00a0al (2015) Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 8:e2358","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"5189_CR25","doi-asserted-by":"publisher","first-page":"e019949","DOI":"10.1161\/JAHA.120.019949","volume":"10","author":"J Bermejo","year":"2021","unstructured":"Bermejo\u00a0J, Gonz\u00e1lez-Mansilla\u00a0A, Mombiela\u00a0T et al (2021) Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival. J\u00a0Am Heart Assoc 10(2):e19949","journal-title":"J Am Heart Assoc"},{"key":"5189_CR26","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","volume":"39","author":"J Bermejo","year":"2018","unstructured":"Bermejo\u00a0J, Yotti\u00a0R, Garc\u00eda-Orta\u00a0R et al (2018) Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a\u00a0multicenter, double-blind, randomized clinical trial. Eur Heart\u00a0J 39:1255\u20131264","journal-title":"Eur Heart J"},{"key":"5189_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jacc.2017.05.052","volume":"70","author":"WT Abraham","year":"2017","unstructured":"Abraham\u00a0WT, Perl\u00a0L (2017) Implantable hemodynamic monitoring for heart failure patients. J\u00a0Am Coll Cardiol 70:389\u2013398","journal-title":"J Am Coll Cardiol"},{"key":"5189_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","volume":"387","author":"WT Abraham","year":"2016","unstructured":"Abraham\u00a0WT, Stevenson\u00a0LW, Bourge\u00a0RC et al (2016) Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387:453\u2013461","journal-title":"Lancet"},{"key":"5189_CR29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","volume":"398","author":"J Lindenfeld","year":"2021","unstructured":"Lindenfeld\u00a0J, Zile\u00a0MR, Desai\u00a0AS et al (2021) Haemodynamic-guided management of heart failure (GUIDE-HF): a\u00a0randomised controlled trial. Lancet 398:991\u20131001","journal-title":"Lancet"},{"issue":"8","key":"5189_CR30","doi-asserted-by":"publisher","first-page":"e006863","DOI":"10.1161\/CIRCHEARTFAILURE.119.006863","volume":"13","author":"DM Shavelle","year":"2020","unstructured":"Shavelle\u00a0DM, Desai\u00a0AS, Abraham\u00a0WT et al (2020) Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS post-approval study. Circ Heart Fail 13(8):e6863","journal-title":"Circ Heart Fail"},{"key":"5189_CR31","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.1943","volume":"22","author":"C Angermann","year":"2020","unstructured":"Angermann\u00a0C, Assmus\u00a0B, Anker\u00a0SD et al (2020) Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European monitoring study for heart failure (MEMS-HF). Eur J Heart Fail 22:1891\u20131901","journal-title":"Eur J Heart Fail"},{"key":"5189_CR32","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/ejhf.2656","volume":"24","author":"B A\u00dfmus","year":"2022","unstructured":"A\u00dfmus\u00a0B, Angermann\u00a0CE, Alkhlout\u00a0B et al (2022) Treatment response to heart failure management guided by remote pulmonary-artery-pressure-monitoring depends on presence and severity of pulmonary hypertension. Eur J Heart Fail 24:2320\u20132330","journal-title":"Eur J Heart Fail"},{"key":"5189_CR33","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/ehf2.13225","volume":"8","author":"JS Tran","year":"2021","unstructured":"Tran\u00a0JS, Havakuk\u00a0O, McLeod\u00a0JM et\u00a0al (2021) Acute pulmonary pressure change after transition to sacubitril\/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail 8:1706\u20131710","journal-title":"ESC Heart Fail"},{"key":"5189_CR34","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1002\/ehf2.13952","volume":"9","author":"P Codina","year":"2022","unstructured":"Codina\u00a0P, Domingo\u00a0M, Barcel\u00f3\u00a0E et\u00a0al (2022) Sacubitril\/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Fail 9:2170\u20132180","journal-title":"ESC Heart Fail"},{"key":"5189_CR35","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/ehf2.12850","volume":"7","author":"W Mullens","year":"2020","unstructured":"Mullens\u00a0W, Martens\u00a0P, Forouzan\u00a0O et\u00a0al (2020) Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring. ESC Heart Fail 7:2071\u20132073","journal-title":"ESC Heart Fail"},{"key":"5189_CR36","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif\u00a0ME, Qintar\u00a0M, Windsor\u00a0SL et al (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation 143:1673\u20131686","journal-title":"Circulation"},{"key":"5189_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","volume":"5","author":"M Packer","year":"2017","unstructured":"Packer\u00a0M, McMurray\u00a0JJV, Krum\u00a0H et al (2017) Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. JACC Heart Fail 5:317\u2013326","journal-title":"JACC Heart Fail"},{"key":"5189_CR38","doi-asserted-by":"publisher","first-page":"1701886","DOI":"10.1183\/13993003.01886-2017","volume":"51","author":"JL Vachiery","year":"2018","unstructured":"Vachiery\u00a0JL, Delcroix\u00a0M, Al-Hiti\u00a0H et al (2018) Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir\u00a0J 51:1701886","journal-title":"Eur Respir J"},{"key":"5189_CR39","unstructured":"the SERENADE Investigators, Shah SJ, Bonderman D, Borlaug BA et\u00a0al A study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction and pulmonary vascular disease (SERENADE). Presented at HFA Heart Failure 2022, Madrid (Abstract)"},{"key":"5189_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","volume":"134","author":"RM Califf","year":"1997","unstructured":"Califf\u00a0RM, Adams\u00a0KF, McKenna\u00a0WJ et\u00a0al (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan international randomized survival trial (FIRST). Am Heart\u00a0J 134:44\u201354","journal-title":"Am Heart J"},{"key":"5189_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijcard.2018.08.080","volume":"272S","author":"S Rosenkranz","year":"2018","unstructured":"Rosenkranz\u00a0S, Lang\u00a0IM, Blind\u00a0R et\u00a0al (2018) Pulmonary hypertension associated with left heart disease: updated recommendations of the Cologne consensus conference 2018. Int J Cardiol 272S:53\u201362","journal-title":"Int J Cardiol"},{"key":"5189_CR42","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/ejhf.2527","volume":"24","author":"TJ Cooper","year":"2022","unstructured":"Cooper\u00a0TJ, Cleland\u00a0JGF, Guazzi\u00a0M et al (2022) Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a\u00a0randomized placebo-controlled multicentre trial. Eur J Heart Fail 24:1239\u20131248","journal-title":"Eur J Heart Fail"},{"key":"5189_CR43","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","volume":"36","author":"E Hoendermis","year":"2015","unstructured":"Hoendermis\u00a0E, Liu\u00a0LCY, Hummel\u00a0YM et\u00a0al (2015) Effects of sildenafil on invasive hemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart\u00a0J 36:2565\u20132573","journal-title":"Eur Heart J"},{"key":"5189_CR44","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","volume":"124","author":"M Guazzi","year":"2011","unstructured":"Guazzi\u00a0M, Vicenzi\u00a0M, Arena\u00a0R, Guazzi\u00a0MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase\u20115 inhibition in a\u00a01-year study. Circulation 124:164\u2013174","journal-title":"Circulation"},{"key":"5189_CR45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","volume":"68","author":"CF Opitz","year":"2016","unstructured":"Opitz\u00a0CF, Hoeper\u00a0MM, Gibbs\u00a0JS et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J\u00a0Am Coll Cardiol 68:368\u2013378","journal-title":"J Am Coll Cardiol"},{"key":"5189_CR46","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2018.12.078","volume":"283","author":"T Kramer","year":"2019","unstructured":"Kramer\u00a0T, Dumitrescu\u00a0D, Gerhardt\u00a0F et al (2019) Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol 283:152\u2013158","journal-title":"Int J Cardiol"},{"key":"5189_CR47","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"SOCRATES-REDUCED Investigators, Gheorghiade\u00a0M, Greene\u00a0SJ, Butler\u00a0J et al (2015) Effect of Vericiguat, a\u00a0soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA 314:2251\u20132262","journal-title":"JAMA"},{"key":"5189_CR48","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske\u00a0B, Maggioni\u00a0AP, Lam\u00a0CSP et al (2017) Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart\u00a0J 38:1119\u20131127","journal-title":"Eur Heart J"},{"key":"5189_CR49","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ejhf.800","volume":"19","author":"G Filippatos","year":"2017","unstructured":"Filippatos\u00a0G, Maggioni\u00a0AP, Lam\u00a0CSP et al (2017) Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail 19:782\u2013791","journal-title":"Eur J Heart Fail"},{"key":"5189_CR50","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong\u00a0PW, Pieske\u00a0B, Anstrom\u00a0KJ et\u00a0al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 382:1883\u20131893","journal-title":"N Engl J Med"},{"key":"5189_CR51","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","volume":"128","author":"D Bonderman","year":"2013","unstructured":"Bonderman\u00a0D, Ghio\u00a0S, Felix\u00a0SB et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a\u00a0phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502\u2013511","journal-title":"Circulation"},{"key":"5189_CR52","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","volume":"43","author":"TM Dachs","year":"2022","unstructured":"Dachs\u00a0TM, Duca\u00a0F, Rettl\u00a0R et\u00a0al (2022) Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur Heart\u00a0J 43:3402\u20133413","journal-title":"Eur Heart J"},{"key":"5189_CR53","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper\u00a0MM, Badesch\u00a0DB, Ghofrani\u00a0HA et\u00a0al (2023) A phase 3 trial of Sotatercept for the treatment of pulmonary arterial hypertension. N\u00a0Engl J Med 388:1478\u20131490","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-023-05189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-023-05189-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-023-05189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T16:08:35Z","timestamp":1690819715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-023-05189-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5189"],"URL":"https:\/\/doi.org\/10.1007\/s00059-023-05189-z","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"27 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.\u00a0Dohr, L.\u00a0Ochs, T.\u00a0Tichelb\u00e4cker and S.\u00a0Baldus declare that they have no competing interests. M.\u00a0Wissm\u00fcller has received remunerations for lectures from Janssen; J.\u00a0Adler has received lecture fees from Janssen and MSD; C.\u00a0Hohmann has received lecture\/consultancy fees from Actelion, Bayer, MSD, and Pfizer; S.\u00a0Rosenkranz has received fees for lectures and\/or consultations from Abbott, Acceleron, Actelion, Aerovate, Altavant, AOP Orphan, AstraZeneca, Bayer, Boehringer-Ingelheim, Edwards, Ferrer, Gossamer, Janssen, MSD, United Therapeutics, and Vifor; his institution has received research grants from Actelion, AstraZeneca, Bayer, and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}